Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014546 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01014546: Clinical Trial Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT01014546 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01014546, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic acid together with ascorbic acid may kill more cancer cells.
Primary Outcome
The frequency of toxicities will be tabulated by grade across all dose levels and courses. The frequency of toxicities will also be tabulated for the dose chosen as the MTD.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Arsenic Trioxide
- DIETARY_SUPPLEMENT Ascorbic Acid
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Why NCT01014546 stopped before completion
NCT01014546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01014546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01014546 about?
NCT01014546 is a clinical study titled "Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis". This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stoppi...
What is the current status of trial NCT01014546?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01014546?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Arsenic Trioxide (DRUG), Ascorbic Acid (DIETARY_SUPPLEMENT), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01014546?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01014546's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia